Therapeutic Management of Immune Thrombocytopenia Case 2 - Episode 7

Mechanism of Action for TPO-RAs in ITP

May 14, 2018

James B. Bussel, MD:One of the things that’s interesting about the thrombopoietin receptor agonists is their mechanism of effect. They’re essentially the only treatments that increase platelet production as a way of bringing up the platelet count. This means that they often may work in people in whom other treatments are not working, and they also may have immunologic effects—for example, as shown by Karina Yazdanbakhsh in several reports—either demonstrating an increase in regulatory T cells or regulatory B cells, both of which are commonly deficient in patients with ITP prior to treatment. So, they may not only bring up the platelet count but have some curative effects as well.

There was an abstract presented at ASH in which they were combined in a large study of 120 patients randomized to either dexamethasone or dexamethasone and a thrombopoietic agent up front for their ITP. And in that study, the cure rate was approximately 20% higher in the preliminary results in the patients who got thrombopoietin receptor agonists in addition to the dexamethasone. In my mind, that’s the first clear clinical study that demonstrated a potential curative effect of the TPO agents. So, this would be another reason how their mechanism might differ from just increasing platelet production.

One final thought going back to the mechanisms of action of thrombopoietic agents is that no treatment works for all patients. There have now been a number of studies, including the one I just alluded to, where agents are combined. It appears that when that is required, hopefully relatively infrequently, using a thrombopoietin receptor agonist as one part of the combination is a very useful way to approach it because of the unique mechanism of effect of these agents and the fact that almost all other agents reduce destruction of antibody-coated platelets, and therefore combining reducing destruction with increased production is seemingly a perfect fit.

Transcript edited for clarity.


Case: A 44-year-old woman presenting with reddish-purple rash on lower legs

February 2017

  • Patient presents with complaints of a reddish-purple rash on her lower legs and “constant” bruises appearing “spontaneously” without her remembering any trauma
  • Physical evaluation reveals:
    • The rash to be petechiae (subcutaneous bleeding)
    • Slightly overweight (BMI = 26.5 kg/m2)
    • Patient is afebrile, with no splenomegaly
  • When asked, reports her menstrual flow is unusually heavy, but says she was evaluated for and had no evidence of fibroids or endometriosis
  • No personal or family history of cancer; no recent viral illnesses; no bone pain
  • Current medications: no chronic medications; acetaminophen as needed; multivitamin
  • Laboratory findings:
    • CBC reveals platelets 21 X 109/L
    • All other findings with normal range
    • Negative forH pylori, HIV, and HCV
  • Diagnosis: chronic ITP
    • Started course of prednisone 1 mg/kg X 21 days, then tapered off; at evaluation, platelets: 27 X 109/L
    • Second course of prednisone 1 mg/kg X 21 days; at evaluation, platelets still <30
    • Third course of prednisone 1 mg/kg X 21 days; at evaluation, platelets still <30

February 2018

  • &ldquo;Rash&rdquo; partly resolved, bruising still present
  • Patient complains of weight gain on treatment and trouble sleeping
  • After discussion with patient, she is started on eltrombopag (PROMACTA), at a dose of 50 mg/day